Aurora Cannabis Expands German Portfolio with Launch of Two New Medical Cannabis Products
LOS ANGELES Aurora Cannabis Inc., a leading manufacturer and supplier of medical cannabis worldwide, announced today the launch of two new high tetrahydrocannabinol (THC) cannabis flower products for medical patients in Germany. The products, Pedanios 27/1 FRG CA and Pedanios 29/1 SRD CA, are the latest additions to the company’s international medical cannabis portfolio, providing physicians with even more options to tailor treatments for their patients.
Dr. Axel Gille, President of Aurora Europe, expressed his excitement about the launch, stating that “the addition of these two high-THC products to our German portfolio gives physicians even more options to provide patients individually tailored treatments.” Aurora is committed to bringing high-quality, innovative cannabis products to patients not only in Germany, but throughout Europe.
Pedanios 27/1 FRG CA and Pedanios 29/1 SRD CA are medical cannabis flowers with a THC content of approximately 27% and 29%, respectively, and a cannabidiol (CBD) content of less than 1%. Both products are proprietary cultivars developed by Aurora’s science and innovation business, Occo, and grown under the highest quality standards under EU GMP certified conditions. The products are hang-dried, hand-finished, and hand-bottled, ensuring that patients receive an exceptional product.
The launch of these two new products comes as Aurora solidifies its position as a market leader in medical cannabis. Providing patients with a range of cannabis products and formats is crucial to individualized and patient-specific care. With this portfolio expansion, Aurora is well-positioned to meet the diverse medical needs of its patients.
In addition to the product launch, Aurora also announced the filing of a final short form base shelf prospectus with securities regulators in most of the provinces of Canada and a corresponding shelf registration statement on Form F-10 with the United States Securities and Exchange Commission. These moves will allow Aurora to raise capital more efficiently and provide the company with the flexibility to pursue growth opportunities as they arise.
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...